Trial updateRetina
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Active, not recruiting. Phase 3. Registered enrolment: 1126. Regeneron Pharmaceuticals
Why it matters
Track this study through NCT06491914. Results are available in the registry.
The study at a glance
- Registry status
- Active, not recruiting
- Phase
- Phase 3
- Registered enrolment
- 1126
- Results posted
- Yes
- Sponsor
- Regeneron Pharmaceuticals
Keep in mind
Registry information describes the study; recruitment status alone does not establish efficacy or safety.
References (1)
Source date: 18 Sept 2026 · United States · Puerto Rico